A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a phase II study.

An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial.

A new, oral ‘first in class’ experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows.